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Faculty
Overview
It is currently a very exciting time in airway disease. 
With recent pivotal changes in the global directives 
in the management for both asthma and COPD, 
new approved treatments and drugs, and innovative 
approaches in characterising the diseases, the time 
was right for assembly 5 (airway diseases, asthma 
and COPD) to undertake a masterclass this year 
in keeping with the new European Respiratory 
Society (ERS) continuing professional development 
initiatives from the Educational Council.
Our aim in developing the structure of the 
masterclass was to provide a “crash course” on the 
critical updates in asthma and COPD, concentrated 
over 2 days, and delivered by experts in the field. 
With participants arriving in Barcelona, Spain, from 
all continents across the globe and enriched by 
those engaging online, the scene was set for an 
exciting 2-day programme (figure 1).
The framework of the masterclass was divided 
into six key sections: guidelines, assessment 
and monitoring, practical workshops, disease 
characterisation, treatments, and clinical cases. 
The course started with Guy Brusselle and Alberto 
Papi highlighting the latest updates in asthma 
and COPD, respectively, noting the changes 
in the management of mild asthma and new 
treatment algorithms in COPD. In the assessment 
and monitoring session, Inigo Ojanguren Arranz 
recapped on the importance of lung function in 
our daily practice, Stelios Loukides reflected on 
the role of fractional exhaled nitric oxide (among 
other measures) in his biomarker talk and, in his 
imaging talk, Sujal Desai reminded us about the 
key radiological features to help in assessing airway 
diseases, with particular attention on recognising 
bronchiectasis.
The practical workshops were, hearteningly, 
very interactive, with participants particularly 
eager to learn about airway hyperresponsiveness 
(from Renaud Louis), exhaled gases and their role 
in the clinic (from Stelios Loukides), the utility of 
induced sputum (from Antonio Spanevello) and 
matching the right inhaler device to the patient 
(from Omar Usmani). Day 1 ended with a riveting 
plenary talk delivered by Alvar Agusti entitled “Do 
airway diseases start in the early life?”
Day 2 started with phenotypes and endotypes 
of asthma (Renaud Louis) and of COPD (Daiana 
Stolz), and in the participant discussion these were 
identified as topics that emerged as most relevant for 
ongoing future research. In the treatment section, 
the role of monoclonal biological therapy in severe 
asthma (Guy Brusselle) and inhaled corticosteroids 
in COPD (Alberto Papi) were intensely discussed by 
the participants. We were reminded of the important 
role of nonpharmacological management in asthma 
and COPD by Andre Nyberg. The lunchtime plenary 
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was entitled “Can bronchiectasis be a negative 
prognostic factor for airways disease?” and was 
given by Montserrat Vendrell.
The afternoon clinical cases session was fast, 
lively and very interactive, with participants 
encouraged to present their own “complex” cases: 
in total eight cases were presented and there 
was great communication among participants in 
suggesting alterative diagnoses and treatment 
approaches. In the closing plenary, Mario Cazzola 
elegantly stepped up and presented “α1-antitrypsin 
deficit: only COPD or asthma as well?”
At the close, participants, chairs and speakers all 
felt that the masterclass had been a clearly focussed 
meeting giving an overview of the key developments 
in airways disease, as well as a forum where 
experts from around the world were able to meet, 
understand different clinical healthcare systems and 
exchange ideas and start collaborations, and, as 
importantly, have fun while doing so. We very much 
enjoyed putting together the programme and hope 
you will be able to join us next time for the assembly 
5 (airway diseases, asthma and COPD) masterclass.
Batyr R. Osmonov, 
Kyrgyzstan, a participant
The course took place on 13–15 June 2019, again 
in the historic and beautiful city of Barcelona, Spain.
I just want to note the excellent organisation 
from the time of registration until the closing of 
the course, by the ERS education team. During the 
course, it was very comfortable, I would even say a 
family atmosphere. The multiple-choice questions 
presented at the end of each presentation gave the 
opportunity for the audience to interact with the 
faculty and even discuss cases in further details.
One very important moment during this event 
was the opportunity to network and build new 
relationships. Having the chance to meet with 
colleagues from all over the world to share best 
practices was very valuable.
It is impossible to underestimate the benefits 
of this masterclass for practitioners and young 
scientists. Everyone could find what was necessary 
and interesting for him: from general principles, 
approaches to the treatment of major obstructive 
diseases, to the subtleties of the approach to 
managing patients with rare obstructive diseases, 
rehabilitation of patients with severe concomitant 
pathologies, etc. There was an opportunity to learn 
new trends in the field of diagnostics, which is just 
as important for the practical work of a doctor.
This is not to mention the great experience that 
I received as a young scientist. The case-based 
sessions really helped in understanding the different 
perspectives and angles from which we can look at a 
case, therefore giving us practical advice and many 
recommendations.
As for the subject matter of the masterclass, it 
is impossible to divide the topics into important 
and/or less important, since each topic, each 
presentation, was invaluable and important for 
any doctor. We can start with the report of Guy 
Brusselle and Alberto Papi on new updates of 
clinical recommendations on bronchial asthma and 
COPD. A lot of publications on these pathologies are 
often contradicting one another and it is sometimes 
difficult to determine which strategy to undertake. 
These presentations were very clear and showed us 
how to act and help our patients.
Subsequent to that, we talked about the 
importance of spirometry, biomarkers and diagnostic 
imaging in obstructive diseases. I also want to flag the 
great debate we had on the themes of spirometry and 
X-ray diagnostics. Very often, many pulmonologists 
encounter mixed spirometry indicators, both 
obstructive and restrictive, and the question arises 
as to what to treat first and what problem prevails in 
the patient and I think all participants found answers 
to their questions in this session.
There was an interesting opinion that it is 
necessary to conduct spirometry at an early 
stage, starting in schools, for the early detection 
and prevention of obstructive diseases. Especially 
since with each new generation we get a deformed 
genotype and a predisposition to new and already 
known respiratory diseases.
The session on inhalation technology was very 
interesting and interactive. A video was shown about 
the inadequacy of the inhalation technique and, as 
well, all the participants conducted training among 
themselves: how to show the patient the correct 
inhalation technique. Personally, there were many 
new facts about the correctness of performance and 
effectiveness of different types of inhalers.
From the first day after I returned home, I started 
using my new knowledge and ideas, and every day 
I apply the experience gained in my practice. I also 
conducted a small masterclass among my colleagues 
so that I could share the knowledge I received.
Figure 1 Faculty and participants in Barcelona for the masterclass in airways disease.
e134 Breathe | December 2019 | Volume 15 | No 4
Masterclass in airways disease
I express my greatest gratitude to the organisers 
of this masterclass and to the ERS for the opportunity 
to participate in such a good event. I would like to 
ask them to carry out further educational schools 
and masterclasses on various topics of respiratory 
medicine and to attract doctors and young scientists 
from developing countries with limited opportunities 
to obtain best practices and the latest updates.
Kostiantyn Dmytriiev, 
Ukraine, a participant
A friendly atmosphere was present throughout the 
course, which provided a nice context to share best 
practices and build new relationships.
Most of the topics covered during the course 
were of the greatest relevance and importance for 
daily clinical practice, while others were setting new 
horizons for the future of scientific research. Each 
topic gave new insight and broadened vision on both 
COPD and asthma. More specifically, I would like to 
mention the last lecture of the first day: “Do airway 
diseases start in the early life?” given by Alvar Agusti. 
In my opinion, it was eye-opening. Alvar Agusti went 
back to the roots of the lung function development 
and decline throughout life, which are relevant for 
clinical practice and for future research as well.
Each topic at the course covered a small part of 
a bigger picture and each topic shaped this picture 
of asthma or COPD management, going back 
from the underlying pathological changes to their 
phenotype manifestations, diagnostic approaches 
and best treatments available. Both lectures on 
clinical guidelines provided information not only on 
guidelines themselves, but also on the statements 
that can be the subject of future research. A block 
of lectures on assessment and monitoring airways 
disease, as well as masterclasses, provided tips for 
better management in these diseases. Lectures on 
phenotyping and endotyping of COPD and asthma 
provided useful information for the assessment and 
differentiation of manifestations of these diseases, 
which is very important. Updates on different types 
of treatment are important and we discussed the 
opportunities to implement some of them in 
everyday practice.
The course outlined the importance of medical 
history, especially in early life, and provided an 
understanding of disease progression. Diagnostic 
work-up and treatment plans can be improved with 
the new information received, especially regarding 
the importance of inhaler use technique in the 
management of airway diseases.
Kseniia Suska, Ukraine, 
a participant
The warmest and friendliest atmosphere of all the 
events I have been fortunate to participate in. There 
were a lot of respectful experts in the field of airway 
diseases who shared their scientific and clinical 
experience with the participants of the masterclass. 
Having all these participants and faculty from all 
over the world allowed us to share our best practices 
and build new relationships.
During the course, topics such as the 
management of asthma and COPD patients, as 
well as lung imaging, were very interesting and 
useful as we face these questions every day in 
our clinical practice. The case-based session 
turned out to be very exciting as it allowed us to 
discuss interesting and difficult cases from daily 
practice. The interaction in this session gave us the 
opportunity to receive good advice from leading 
experts. The practical workshops on induced 
sputum, inhalation techniques, exhaled gases, 
airway hyperresponsiveness and its practical clinical 
application have been incredibly useful, and I plan 
to apply this knowledge in my clinical practice.
During this course I realised that the clinical 
condition of the patients is the main biomarker, 
which should be decisive in choosing the strategy 
for managing patients with airway diseases.
I would like to thank the ERS and the organising 
committee of the masterclass for the opportunity to 
participate in such an informative scientific event.
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